United Therapeutics

YTD

ALL

Trade United Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About UTHR

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin.

CEO

Martine A. Rothblatt

CEOMartine A. Rothblatt

Employees

1,400

Employees1,400

Headquarters

Silver Spring, Maryland

HeadquartersSilver Spring, Maryland

Founded

1996

Founded1996

Employees

1,400

Employees1,400

UTHR Key Statistics

Market cap

23.86B

Market cap23.86B

Price-Earnings ratio

19.06

Price-Earnings ratio19.06

Dividend yield

—

Dividend yield—

Average volume

641.76K

Average volume641.76K

High today

$541.03

High today$541.03

Low today

$524.58

Low today$524.58

Open price

$534.84

Open price$534.84

Volume

966.46K

Volume966.46K

52 Week high

$609.35

52 Week high$609.35

52 Week low

$292.34

52 Week low$292.34

Stock Snapshot

United Therapeutics(UTHR) stock is priced at $538.84, giving the company a market capitalization of 23.86B. It carries a P/E multiple of 19.06.

On 2026-08-09, United Therapeutics(UTHR) stock traded between a low of $524.58 and a high of $541.03. Shares are currently priced at $538.84, which is +2.7% above the low and -0.4% below the high.

The United Therapeutics(UTHR)'s current trading volume is 966.46K, compared to an average daily volume of 641.76K.

In the last year, United Therapeutics(UTHR) shares hit a 52-week high of $609.35 and a 52-week low of $292.34.

UTHR News

Simply Wall St 2d

Stronger EPS, Ralinepag Progress, and Buybacks Might Change The Case For Investing In United Therapeutics - simplywall.st

...

TipRanks 4d

United Therapeutics reports Q2 EPS $7.27, consensus $6.86

Reports Q2 revenue $783.3M, consensus $804.65M. “We just submitted what we believe are two of the most important NDAs in rare pulmonary disease history: ralinep...

Nasdaq 4d

United Therapeutics Corp Bottom Line Climbs In Q2

(RTTNews) - United Therapeutics Corp (UTHR) announced a profit for its second quarter that Increased, from the same period last year The company's earnings tot...

Analyst ratings

81%

of 16 ratings

Buy

81.3%

Hold

18.8%

Sell

People also own

Based on the portfolios of people who own UTHR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.